Desipramine reverses remote memory deficits by activating calmodulin-CaMKII pathway in a UTX knockout mouse model of Kabuki syndrome
View abstract on PubMed
Summary
This summary is machine-generated.This study reveals that UTX gene dysfunction impairs cognitive function in Kabuki syndrome by affecting epigenetic regulation. The drug desipramine shows potential for treating cognitive deficits in KS patients.
Area Of Science
- Epigenetics
- Neuroscience
- Developmental Biology
Background
- Kabuki syndrome (KS) is a rare genetic disorder with intellectual disability.
- The UTX gene, encoding a histone demethylase, is a key risk gene for KS.
- The precise role of UTX in cognitive function and potential treatments for KS remain largely unknown.
Purpose Of The Study
- To investigate the regulatory role of UTX in cognitive processes.
- To elucidate the molecular mechanisms behind UTX dysfunction in KS.
- To identify potential therapeutic targets for KS-associated cognitive impairments.
Main Methods
- Generation of UTX conditional knockout mice.
- Analysis of calmodulin gene transcription and H3K27me3 demethylation.
- Assessment of synaptic plasticity and memory in mice.
Main Results
- UTX deletion downregulated calmodulin transcription via disrupted H3K27me3 demethylation.
- UTX-knockout mice exhibited impaired long-term potentiation and memory deficits.
- Administration of desipramine reversed the observed cognitive impairments.
Conclusions
- UTX plays a critical role in synaptic plasticity and cognition through an epigenetic mechanism.
- Desipramine represents a potential therapeutic strategy for Kabuki syndrome.
- This research provides insights into the molecular basis of KS and potential treatment avenues.

